Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RMHEN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PRO1107
|
|||||
| Synonyms |
PRO1107; GEN1107
Click to Show/Hide
|
|||||
| Organization |
ProfoundBio (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
|
|
||||||
| Antibody Name |
Anti-PTK7 antibody
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase 7 (PTK7)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
LD343
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Fallopian tube cancer |
1 Trials
|
||||||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Peritoneal cancer |
1 Trials
|
||||||||
| Urothelial cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients had advanced/metastatic PTK7-positive solid tumors (e.g., ovarian, NSCLC, TNBC) with measurable disease, ECOG 0-1, and no prior anti-PTK7 therapy or uncontrolled comorbidities; exclusions included recent ADC progression, active CNS metastases, or infections.
|
||||
| Administration Dosage |
PRO1107 monotherapy in escalating doses in Part A and at the two recommended phase 2 doses in Part B
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06171789 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study assessed adverse events, lab abnormalities, and dose-limiting toxicities over 1 year, including type, incidence, severity, and relatedness.
|
||||
| Other Endpoint |
Key efficacy outcomes included ORR, DCR, PFS, and duration of response per RECIST v1.1, alongside pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2, Ctrough) for PRO1107 over 1 year.
|
||||